GHRP-2 Research & Studies
Part of the full GHRP-2 guide - a synthetic hexapeptide growth hormone secretagogue reference compound, identity-verified with a COA on every vial.
In brief
The research record assembled for GHRP-2 is built from five primary sources that, together, define the peptide as a ghrelin-receptor agonist studied across transfected cell lines, isolated pituitary tissue, and cultured myocytes. Rather than rehearsing the mechanism, this section maps what each cited investigation actually examined and which in-vitro or preclinical model it used. The foundational thread begins with the receptor's discovery, extends through direct cellular pharmacology, and includes structure-activity context from within the growth hormone secretagogue class. Every model context described here is attributable to the provided citations and the listed research areas; no additional studies, endpoints, or numerical results are introduced beyond what those sources support. The result is a focused picture of receptor-binding pharmacology, signal-transduction characterization, and receptor-specificity profiling, all framed at the level of receptors, cells, and isolated tissue preparations.
The detail
A closer look
01
Receptor discovery as the foundation
Howard et al. (Science 1996; PMID 8688086) reported a receptor in pituitary and hypothalamus that functions in growth hormone release. This is the cornerstone citation: it describes the cloning and characterization of GHS-R1a, the molecular target that GHRP-2 engages. Within the research framework, this work defines the conserved ligand-activation domain at which the peptide binds and establishes the receptor as a Gq/11-coupled GPCR. All subsequent GHRP-2 pharmacology, including agonist binding studies in receptor-transfected cell lines, is interpretable only because this receptor was first identified and cloned. The paper anchors the 'GHS-R1a binding and agonist pharmacology' research area by providing the receptor itself.
02
Direct cellular action and receptor-specificity profiling
Yamamoto et al. (Life Sciences 2008; PMID 18191156) studied GHRP-2 as a GHS-R agonist acting directly on myocytes, and reported that the GHS-R1a antagonist [D-Lys3]-GHRP-6 blocks its effects in the C2C12 cultured myocyte line. This citation underpins the 'receptor-specificity profiling using [D-Lys3]-GHRP-6 antagonist blockade in cultured myocytes (C2C12)' research area. It demonstrates that the peptide engages cells expressing the ghrelin receptor and that a selective antagonist removes the response, the classic pharmacological design for confirming on-target activity. The model context is a cultured skeletal-muscle cell line, situating part of the GHRP-2 record outside the pituitary in a receptor-defined in-vitro system.
03
Pituitary secretory models and class context
Kageyama et al. (Regulatory Peptides 2009; PMID 19682503) examined GHRP-2 stimulation of secretion and synthesis of adrenocorticotropic hormone in mouse pituitary, extending the cellular pharmacology into anterior pituitary secretory-cell biology and supporting the 'in-vitro anterior pituitary somatotroph secretory-granule exocytosis' research theme. Bowers (Cellular and Molecular Life Sciences 1998; PMID 9893708) provides growth-hormone-releasing-peptide class context, informing the 'comparative structure-activity studies within the GHS / ghrelin-mimetic peptide class' research area. Pihoker et al. (JCEM 1998; PMID 9543135) is cataloged as a pharmacokinetic and pharmacodynamic characterization of GHRP-2. Together these sources frame the peptide within ghrelin-mimetic secretagogue pharmacology and pituitary secretory-cell models, the contexts named in the provided research areas.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. GHRP-2 is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.